ProCE Banner Activity

Nivolumab or Ipilimumab ± Azacitidine in Treatment-Naive or HMA-Failed Myelodysplastic Syndromes

Slideset Download
Conference Coverage
Preliminary phase II data suggest promising activity of single-agent ipilimumab and nivolumab plus azacitidine in a molecularly high-risk population of MDS patients.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen